Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients - Moberly, James B.; Ford, Daniel M.; Zahir, Hamim; Chen, Shuquan; Mochizuki, Takashi; Truitt, Kenneth E.; Vollmer, Timothy L. (Journal of Neuroimmunology, 2012)
Keywords: Administration, Oral; Allergy and Immunology; Amino Alcohols; Amino Alcohols - adverse effects; Amino Alcohols - pharmacokinetics; Amino Alcohols - pharmacology; Autoimmune disease; Bradycardia; CD4-Positive T-Lymphocytes; CD4-Positive T-Lymphocytes - drug effects; CD4-Positive T-Lymphocytes - immunology; CD4-Positive T-Lymphocytes - pathology; CD8 T cell subsets; Dose-Response Relationship, Immunologic; Down-Regulation; Down-Regulation - drug effects; Down-Regulation - immunology; Fingolimod; Humans; Lymphocyte Subsets; Lymphocyte Subsets - drug effects; Lymphocyte Subsets - immunology; Lymphocyte Subsets - pathology; Lymphopenia; Lymphopenia - immunology; Lymphopenia - metabolism; Lymphopenia - pathology; Lysophospholipids; Lysophospholipids - metabolism; Multiple Sclerosis; Multiple Sclerosis - drug therapy; Multiple Sclerosis - immunology; Multiple Sclerosis - pathology; Neurology; Pilot Projects; Pyrroles; Pyrroles - adverse effects; Pyrroles - pharmacokinetics; Pyrroles - pharmacology; Receptors, Lysosphingolipid; Receptors, Lysosphingolipid - metabolism; S1PR1; Sphingosine; Sphingosine - analogs & derivatives; Sphingosine - metabolism; S1PR1; Autoimmune disease; Bradycardia; Lymphopenia; Fingolimod; CD8 T cell subsets